



Contacts:

Robert Towarnicki
Nucleonics, Inc.
(267) 518-0101
rtowarnicki@nucleonicsinc.com

L. Janet Milton
Apath, L.L.C.
(314) 812-8160
Milton@apath.com

For Media:
Joan Kureczka
Kureczka/Martin Associates
(415) 821-2413
Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

Nucleonics Licenses Key Apath Technology for Use in Hepatitis C Therapeutic

HORSHAM, PA and SAINT LOUIS, MO (November 17, 2004): Nucleonics, Inc. and Apath, L.L.C. today announced that Nucleonics has received a non-exclusive license to Apath technology related to the 3' non-translated region of the Hepatitis C viral genome, which Nucleonics is using as a target in its development of an expressed RNAi therapeutic against Hepatitis C. Financial details of the license agreement were not disclosed.

"Nucleonics has continued to build its intellectual property portfolio to support our product development efforts in the areas of Hepatitis B and C," said Robert J. Towarnicki, president and chief executive officer of Nucleonics, Inc. "We have designed a therapeutic candidate against Hepatitis C that targets this region of the Hepatitis C viral genome, and this license to Apath's gene discoveries in this area gives us the freedom to move forward in its development."

"We are very pleased to grant this license to Nucleonics," said Charles M. Rice, Ph.D., Apath founder and managing director. "This license agreement further validates the importance of Apath's genetic discoveries in the area of Hepatitis C and other medically important human viral pathogens."

About Apath, L.L.C.

Apath, L.L.C. is a privately held pharmaceutical discovery company, with a focus on the development of broad-spectrum therapeutics for RNA viral diseases. Apath was founded in St. Louis, Missouri in 1997 by Charles M. Rice, Ph.D., currently professor of Molecular Biology at The Rockefeller University, and formerly with the Washington University School of Medicine.

About Nucleonics, Inc.

Nucleonics, founded in January 2001, is an emerging biotechnology company focused on the development of novel RNA interference-based therapeutics for viral and other diseases. Privately owned Nucleonics is headquartered in Horsham, Pennsylvania.

###